As one of the DHA transporters (another known is Fatp4), the alteration in the expression of ACSL6 may be a risk factor for an exacerbation of cognitive and neurological deficits in patients with AD (Pontifex et al., 2021). Here, ACSL6 is linked to Alzheimer disease.